This morning we watched Charles River Laboratories International drop -3.0% to a price of $96.97 per share. The Mid-Cap Biotechnology company is now trading -43.44% below its average target price of $171.44. Analysts have set target prices ranging from $101.0 to $215.0 per share for Charles River Laboratories International, and have given the stock an average rating of hold.
The stock has an above average percentage of its shares sold short at 8.4%, and a short ratio of 2.17. Only 0.88% of the company's shares are owned by insiders, indicating that management does not have a deep alignment of interest with its shareholders. Finally, we also note that a significant number of institutional investors are invested in the stock, with 110.2% of Charles River Laboratories International's shares being owned by this investor type.
Institutions Invested in Charles River Laboratories International
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2024-12-31 | Vanguard Group Inc | 13% | 6,158,926 | $597,231,061 |
| 2024-12-31 | Blackrock Inc. | 9% | 4,232,170 | $410,393,530 |
| 2024-12-31 | Wellington Management Group, LLP | 8% | 4,076,426 | $395,291,034 |
| 2024-12-31 | State Street Corporation | 4% | 2,181,430 | $211,533,269 |
| 2024-12-31 | Allspring Global Investments Holdings, LLC | 4% | 1,808,002 | $175,321,956 |
| 2024-12-31 | Kayne Anderson Rudnick Investment Management LLC | 4% | 1,805,541 | $175,083,312 |
| 2024-12-31 | Geode Capital Management, LLC | 3% | 1,233,211 | $119,584,472 |
| 2024-12-31 | Impactive Capital, LP | 2% | 1,202,339 | $116,590,814 |
| 2024-12-31 | Meritage Group, LP | 2% | 1,074,120 | $104,157,417 |
| 2024-12-31 | Ariel Investments, LLC | 2% | 1,067,327 | $103,498,700 |
Besides an analyst consensus of strong upside potential, other market factors point to there being mixed market sentiment on Charles River Laboratories International.
